Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Phase II Study of Intravenous 852A in Unresectable Metastatic Cutaneous Melanoma
2004-003910-41Phase 2Completed
- Sponsor
- 3M
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 852A in cutaneous melanoma (CM) and melanoma, sponsored by 3M. Primary endpoint: Overall tumor response. Started Feb 2005; status: completed.
02
Drugs
852A
03
Conditions
cutaneous melanoma (CM)melanoma
Beyond the preview
Go deeper on 2004-003910-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003910-41.